Evidence map›Paper›PMID 29656138›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2018

Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.

Jeannine S McCune, Barry Storer, Sushma Thomas, Jožefa McKiernan, Rohan Gupta, Brenda M Sandmaier

Abstract read
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeannine S McCuneSchool of Pharmacy, University of Washington, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Department of Population Sciences, City of Hope, Duarte, California; Department of Hematology and HCT, City of Hope, Duarte, California. Electronic address: jmccune@coh.org.
Barry StorerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Sushma ThomasClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jožefa McKiernanDepartment of Population Sciences, City of Hope, Duarte, California.
Rohan GuptaDepartment of Hematology and HCT, City of Hope, Duarte, California.
Brenda M SandmaierClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.

Funding

VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STEPHANIE J LEE · 1985 to 2026
$128.4M
Project 3: Stem Cell Allografts for Lymphoid MalignanciesP01CA078902 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SANDMAIER, BRENDA MARIE · 1999 to 2025
$46.1M
UNRELATED AND HLA-MISMATCHED RELATED DONOR TRANSPLANTSP01HL036444 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAWLINGS, DAVID J · 1986 to 2010
$25.9M
TRANSPLANTATION IMMUNOLOGYP01AI033484 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MARTIN, PAUL J · 1992 to 2013
$13.1M
Whole Genome Association Analysis of Hematopoietic Cell Transplant OutcomeR01HL087690 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HANSEN, JOHN ANDREW · 2006 to 2008
$4.1M
Population Pharmacokinetics/Pharmacodynamics in Nonablative Stem Cell RecipientsR01HL091744 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCCUNE, JEANNINE S · 2008 to 2011
$2.0M
NCI NIH HHS P01 CA018029NCI NIH HHS P01 CA078902NHLBI NIH HHS P01 HL036444NHLBI NIH HHS R01 HL087690NHLBI NIH HHS R01 HL091744NIAID NIH HHS P01 AI033484
6 · The paper itself

Abstract

We evaluated inosine monophosphate dehydrogenase (IMPDH) 1 and IMPDH2 pharmacogenetics in 247 recipient-donor pairs after nonmyeloablative hematopoietic cell transplant (HCT). Patients were conditioned with total body irradiation + fludarabine and received grafts from related or unrelated donors (10% HLA mismatch), with postgraft immunosuppression of mycophenolate mofetil (MMF) with a calcineurin inhibitor. Recipient and donor IMPDH genotypes (rs11706052, rs2278294, rs2278293) were not associated with day 28 T cell chimerism, acute graft-versus-host disease (GVHD), disease relapse, cytomegalovirus reactivation, nonrelapse mortality, or overall survival. Recipient IMPDH1 rs2278293 genotype was associated with a lower incidence of chronic GVHD (hazard ratio, .72; P = .008) in nonmyeloablative HCT recipients. Additional studies are needed to confirm these results with the goal of identifying predictive biomarkers to MMF that lower GVHD.

Indexed as

AdolescentAdultAgedChildFemaleHematopoietic Stem Cell TransplantationHumansInosine MonophosphateMaleMiddle AgedPharmacogeneticsPrecision MedicineTransplantation ConditioningYoung AdultInosine MonophosphateGraft-versus-host diseaseHematopoietic cell transplantIMPDHMPAPharmacogenomicsPrecision medicine

Identifiers

PMID29656138
PMCPMC6414227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.